» Articles » PMID: 20129251

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

Abstract

The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.

Citing Articles

Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance.

DAprile S, Denaro S, Gervasi A, Vicario N, Parenti R Front Cell Dev Biol. 2025; 13:1535073.

PMID: 40078366 PMC: 11897528. DOI: 10.3389/fcell.2025.1535073.


A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy.

Buzatu I, Tataranu L, Duta C, Stoian I, Alexandru O, Dricu A Int J Mol Sci. 2025; 26(5).

PMID: 40076810 PMC: 11899917. DOI: 10.3390/ijms26052192.


Immune Cell Interplay in the Fight Against GBM.

Vallieri N, Datsi A Cancers (Basel). 2025; 17(5).

PMID: 40075663 PMC: 11899300. DOI: 10.3390/cancers17050817.


Clinical Impact of a Next-Generation Sequencing Approach for Glioblastoma Patients.

Vivancos Sanchez C, Esteban Rodriguez M, Pelaez Garcia A, Taravilla-Loma M, Rodriguez-Dominguez V, Rodriguez-Antolin C Cancers (Basel). 2025; 17(5).

PMID: 40075591 PMC: 11898826. DOI: 10.3390/cancers17050744.


Mapping glioma progression: single-cell RNA sequencing illuminates cell-cell interactions and immune response variability.

Li X, Chen S, Ding M, Ding H, Yang K Discov Oncol. 2025; 16(1):302.

PMID: 40072722 PMC: 11903997. DOI: 10.1007/s12672-025-01903-x.


References
1.
Curran Jr W, Scott C, Horton J, Nelson J, Weinstein A, Fischbach A . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85(9):704-10. DOI: 10.1093/jnci/85.9.704. View

2.
Kleihues P, Ohgaki H . Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 2001; 1(1):44-51. PMC: 1919466. DOI: 10.1093/neuonc/1.1.44. View

3.
Mischel P, Shai R, Shi T, Horvath S, Lu K, Choe G . Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003; 22(15):2361-73. DOI: 10.1038/sj.onc.1206344. View

4.
Huber W, Gentleman R . matchprobes: a Bioconductor package for the sequence-matching of microarray probe elements. Bioinformatics. 2004; 20(10):1651-2. DOI: 10.1093/bioinformatics/bth133. View

5.
Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View